Results 71 to 80 of about 2,468 (182)

2025 Guidelines for direct oral anticoagulants: a practical guidance on the prescription, laboratory testing, peri‐operative and bleeding management

Internal Medicine Journal, Volume 55, Issue 7, Page 1174-1183, July 2025.
Abstract Direct oral anticoagulants (DOACs) are widely prescribed to prevent and treat venous and arterial thromboembolism, supported by published evidence, and are preferred over warfarin in many guidelines. Although the risk of major bleeding, in particular intracranial haemorrhage (ICH), is decreased with DOACs, gastrointestinal bleeding is ...
Huyen A. Tran, Eileen Merriman, Ross Baker, Jennifer Curnow, Laura Young, Chee Wee Tan, Simon McRae, Sanjeev D. Chunilal   +7 more
wiley   +1 more source

Successful intravenous thrombolysis in acute ischemic stroke after reversal of dabigatran etexilate with idarucizumab at the end of therapeutic time window

Turkish Journal of Emergency Medicine, 2020
Dabigatran is a direct oral anticoagulant that is widely used for stroke prevention in patients with atrial fibrillation. We report a case of an 80-year-old stroke patient on dabigatran for permanent atrial fibrillation, who presented with an initial ...
Gorana Vukorepa, Sabina Deveđija*, Miljenko Crnjaković, Mirna Karakaš, Zeljka Cuk   +4 more
doaj   +1 more source

Intravenous Thrombolysis in Patients Taking Direct Oral Anticoagulation Treatment Before Stroke Onset: Results from the Safe Implementations of Treatments in Stroke International Stroke Registry

Annals of Neurology, Volume 97, Issue 6, Page 1205-1214, June 2025.
Objectives Intravenous thrombolysis (IVT) is contraindicated for acute ischemic stroke (AIS) patients taking direct oral anticoagulants (DOACs) within 48 hours before index stroke. Limited data exist on off‐label use of IVT for these patients. We compared the safety and outcomes of IVT in AIS patients with DOAC treatment and patients with no OAC before
Marius Matusevicius, Malin Säflund, Maurizio Balestrino, Manuel Cappellari, Delfina Ferrandi, Abdoreza Ghoreishi, André Peeters, Viiu‐Marika Rand, Manuela De Michele, Aleksandras Vilionskis, Andrea Zini, Niaz Ahmed   +11 more
wiley   +1 more source

External validation of the Haemorrhage Estimate Risk in Oral anticoagulation for Mild head trauma nomogram in Hong Kong

Hong Kong Journal of Emergency Medicine, Volume 32, Issue 2, April 2025.
Abstract Objective Currently, there is no consensus among international guidelines on the management of patients with mild traumatic brain injuries (MTBIs) who are on direct oral anti‐coagulants (DOACs). Overuse of computed tomography (CT) scan of the brain results in unnecessary radiation exposure, longer waits and higher costs.
Ho Man Cheng, Jerome Lok Tsun So, Rex Pui Kin Lam, Hon Wah Ng   +3 more
wiley   +1 more source

Use of idarucizumab in reversing dabigatran anticoagulant effect: a critical appraisal [PDF]

, 2018
Use of non-vitamin K antagonist oral anticoagulants is spreading in the real world. Despite that, a strong need for antidotes/reversal agents is still reported by several physicians.
Boriani, Giuseppe, Proietti, M, Proietti, Marco, Boriani, G   +3 more
core   +1 more source

Intravenous Thrombolysis after Reversal of Dabigatran by Idarucizumab: A Case Report

Case Reports in Neurology, 2016
We describe a 75-year-old female patient with nonvalvular atrial fibrillation who presented with acute ischemic stroke during treatment with dabigatran 2 × 110 mg per day.
Waldemar Kafke, Peter Kraft, Department of Neurology   +2 more
doaj   +1 more source

Idarucizumab for dabigatran reversal

Thrombosis research, 2023
Background: Idarucizumab has been approved to reverse the anticoagulant effect of dabigatran. However, there is little knowledge of the effectiveness and safety of idarucizumab in daily practice. Aims: This systematic review and meta-analysis aims to evaluate the use, effectiveness and outcomes of idarucizumab.
van der Horst, S. F. B., Martens, E. S. L., den Exter, P. L., Bos, M. H. A., van Mens, T. E., Huisman, M. V., Klok, F. A.   +6 more
openaire   +1 more source

First Reported Case of Hemopericardium Related to Dabigatran Use Reversed by New Antidote Idarucizumab

Case Reports in Cardiology, 2017
Dabigatran, the first novel oral anticoagulant (NOAC) with a reversal agent, heralded a paradigm shift in the treatment of nonvalvular atrial fibrillation.
Steven Song, Joselle Cook, Clive Goulbourne, Matthew Meade, Louis Salciccioli, Jason Lazar   +5 more
doaj   +1 more source

Direct oral anticoagulants: first airbag

Медицинский совет, 2019
The safety profile of oral anticoagulants (DOACs) was confirmed in the large-scale studies, the increased risk of hemorrhagic events does still exist, which may be caused by the nature of the patient’s concomitant pathology, the resulting injury or the ...
A. N. Sokolova, A. I. Skripka
doaj   +1 more source

JCS/JHRS 2024 Guideline Focused Update on Management of Cardiac Arrhythmias

Journal of Arrhythmia, Volume 41, Issue 3, June 2025.
Yu‐ki Iwasaki, Takashi Noda, Masaharu Akao, Tadashi Fujino, Teruyuki Hirano, Koichi Inoue, Kengo Kusano, Toshiyuki Nagai, Kazuhiro Satomi, Tetsuji Shinohara, Kyoko Soejima, Yohei Sotomi, Shinya Suzuki, Teiichi Yamane, Tsukasa Kamakura, Hiroyuki Kato, Arimi Katsume, Yusuke Kondo, Kenji Kuroki, Hisaki Makimoto, Hiroshige Murata, Takafumi Oka, Nobuaki Tanaka, Nobuhiko Ueda, Hiro Yamasaki, Seigo Yamashita, Ryobun Yasuoka, Kenji Yodogawa, Kazutaka Aonuma, Takanori Ikeda, Toru Minamino, Hideo Mitamura, Akihiko Nogami, Ken Okumura, Hiroshi Tada, Takashi Kurita, Wataru Shimizu, on behalf of the Japanese Circulation Society and Japanese Heart Rhythm Society Joint Working Group   +37 more
wiley   +1 more source